Many malignant tumors, including pancreatic cancer, breast cancer, and prostate cancer have up-regulated SLC2A1, and the level of SLC2A1 is closely related to the clinical stage, degree of differentiation and lymph node metastasis of pancreatic cancer (Liu et al., 2012). This evidence concerns the gene SLC2A1 and prostate cancer.